Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Estimated cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States

View Full Paper
Ask AI
Bookmark
Share

Authors

SCSwetha ChallagullaQFQianhong FuRWRhys Williams

Discussion

Loading...

Member takes

Overview

Modeling analysis estimates cardiac deaths in CLL, revealing potential benefits of zanubrutinib over ibrutinib.

Key Points

  • Up to 255 cardiac deaths may be avoided when using zanubrutinib instead of ibrutinib in CLL treatment.
  • Real-world data from 39,738 patients treated with ibrutinib were analyzed for cardiac death risks.
  • Model analysis calculated a number needed to treat of 54 for 2L+ CLL patients to prevent cardiac deaths.
  • The findings suggest further real-world validation is needed to confirm the cardiac death risk differences.

Cite This Study

Challagulla et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3f8https://doi.org/10.1182/blood-2025-7443
View Full Paper
Ask AI
Bookmark
Share